Corvus Pharmaceuticals (CRVS) Current Deferred Revenue (2015 - 2018)

Corvus Pharmaceuticals' Current Deferred Revenue history runs 4 years deep, the most recent figure standing at $160000.0 for Q4 2018.

• In Q4 2018, Current Deferred Revenue fell 60.98% year-over-year to $160000.0; the TTM figure through Dec 2018 stood at $160000.0 (down 60.98% YoY), while the FY2018 annual figure was $160000.0, down 60.98% from the prior year.
• Current Deferred Revenue for Q4 2018 stood at $160000.0, down from $435000.0 in the prior quarter.
• The five-year high for Current Deferred Revenue was $435000.0 in Q3 2018, with the low at $160000.0 in Q4 2018.
• The 4-year median for Current Deferred Revenue is $386000.0 (2017), against an average of $350000.0.
• The sharpest annual moves came in 2016 and 2018: Current Deferred Revenue soared 69.51% in 2016, then plunged 60.98% in 2018.
• Corvus Pharmaceuticals' Current Deferred Revenue stood at $223000.0 in 2015, then jumped by 69.51% to $378000.0 in 2016, then gained by 8.47% to $410000.0 in 2017, then slumped by 60.98% to $160000.0 in 2018.
• Business Quant data shows CRVS's Current Deferred Revenue at $160000.0 in Q4 2018, $435000.0 in Q3 2018, and $427000.0 in Q2 2018.